Allergan (AGN)

166.47 +0.74 (0.45%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (10/30/19 *Est.)
- M&A (N/A)

Latest Headlines

Form 6-K AEGON NV For: Sep 18 September 18, 2019 6:50 AM - SEC Filing Aegon announces purchase of shares to neutralize 2019 interim stock dividend September 18, 2019 2:00 AM - BizWire Aegon announces purchase of shares to neutralize 2019 interim stock dividend September 18, 2019 2:00 AM - BizWire Announcement under the Irish Takeover Rules: Relevant Securities in Issue - September 17, 2019 September 17, 2019 4:15 PM - PR NewsWire Allergan Announces Commencement of Mailing of Proxy Statement September 17, 2019 7:30 AM - PR NewsWire Form 8-K Allergan plc For: Sep 16 September 16, 2019 4:17 PM - SEC Filing Form DEFM14A Allergan plc September 16, 2019 4:02 PM - SEC Filing Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan September 12, 2019 6:22 PM - StreetInsider AM Best Downgrades Credit Ratings of Aegon N.V.’s U.S. Subsidiaries September 12, 2019 10:14 AM - BizWire Allergen (AGN) PT Raised to $189 at UBS September 12, 2019 6:02 AM - StreetInsider Form 8-K Allergan plc For: Sep 10 September 11, 2019 6:36 AM - SEC Filing Form DEFA14A Allergan plc September 11, 2019 6:35 AM - SEC Filing Allergan Shareholder Meetings Scheduled for October 14, 2019 September 10, 2019 4:36 PM - PR NewsWire Form 6-K AEGON NV For: Sep 10 September 10, 2019 6:10 AM - SEC Filing Mike Holliday-Williams to succeed Adrian Grace as CEO of Aegon UK September 10, 2019 2:00 AM - BizWire Mike Holliday-Williams to succeed Adrian Grace as CEO of Aegon UK September 10, 2019 2:00 AM - BizWire Allergan (AGN), Molecular Partners Report FDA Approval for Biologics License Application & EMA Validated Marketing Authorisation for Abicipar pegol September 9, 2019 7:36 AM - StreetInsider Allergan and Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation for Abicipar pegol in Patients with Neovascular (Wet) Age-re September 9, 2019 7:30 AM - PR NewsWire Allergan (AGN) Receives FDA Approval of Juvederm VOLUMA XC For Mid-Face Injection Via Cannula September 3, 2019 7:32 AM - StreetInsider Allergan Receives FDA Approval of Juvéderm VOLUMA® XC For Mid-Face Injection Via Cannula September 3, 2019 7:30 AM - PR NewsWire Allergan (AGN) Settles with Two Ohio Plaintiffs in Federal Opioid Litigation August 30, 2019 7:01 AM - StreetInsider Allergan Announces Settlement with Two Ohio Plaintiffs in Federal Opioid Litigation August 30, 2019 7:00 AM - PR NewsWire J&J liable for $572 million in Oklahoma opioid epidemic trial; shares rise August 26, 2019 6:11 AM - StreetInsider Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab) August 22, 2019 9:00 AM - PR NewsWire Form 6-K AEGON NV For: Aug 15 August 15, 2019 10:38 AM - SEC Filing Form 6-K AEGON NV For: Jun 30 August 15, 2019 6:24 AM - SEC Filing Form 6-K AEGON NV For: Aug 15 August 15, 2019 6:22 AM - SEC Filing Aegon reports first half 2019 results August 15, 2019 1:30 AM - BizWire Aegon reports first half 2019 results August 15, 2019 1:30 AM - BizWire Sachem Head Adds Salesforce (CRM), Spectra Energy (SE) - 13F August 14, 2019 5:15 PM - StreetInsider Paulson's 13F Shows New Stakes in Sotheby's (BID), Lyft (LYFT), Increase in Allergan (AGN), Sprint (S) (more...) August 14, 2019 5:10 PM - StreetInsider Appaloosa's 13F Shows Reduced Stakes in Allergan (AGN), Facebook (FB), Micron (MU), Exits Alibaba (BABA) (More...) August 14, 2019 4:46 PM - StreetInsider Baupost's 13F Shows New Stake in XPO Logistics (XPO), Increase in Bristol-Myers Squibb (BMY), CBS (CBS), Liquidated Celgene (CELG) (More...) August 13, 2019 5:28 PM - StreetInsider Form PREM14A Allergan plc For: Aug 12 August 12, 2019 4:33 PM - SEC Filing Form 6-K AEGON NV For: Aug 12 August 12, 2019 8:04 AM - SEC Filing Lard Friese to succeed Alex Wynaendts as Aegon’s CEO August 12, 2019 1:00 AM - BizWire Lard Friese to succeed Alex Wynaendts as Aegon’s CEO August 12, 2019 1:00 AM - BizWire Allergen (AGN) PT Lowered to $157 at Piper Jaffray August 7, 2019 6:59 AM - StreetInsider Allergen (AGN) PT Raised to $165 at Cantor Fitzgerald August 7, 2019 6:42 AM - StreetInsider Allergen (AGN) PT Raised to $188 at Barclays August 7, 2019 6:18 AM - StreetInsider Guggenheim Downgrades Allergen (AGN) to Neutral August 7, 2019 6:16 AM - StreetInsider Form 8-K Allergan plc For: Aug 06 August 6, 2019 8:52 AM - SEC Filing Form 8-K Allergan plc For: Aug 06 August 6, 2019 7:16 AM - SEC Filing Allergan (AGN) Tops Q2 EPS by 3c August 6, 2019 7:06 AM - StreetInsider Allergan Reports Second Quarter 2019 Financial Results August 6, 2019 7:02 AM - PR NewsWire Form 6-K AEGON NV For: Aug 05 August 5, 2019 7:23 AM - SEC Filing Aegon completes share buyback program August 2, 2019 2:00 PM - BizWire Aegon completes share buyback program August 2, 2019 2:00 PM - BizWire Allergan to Report Second Quarter 2019 Financial Results August 2, 2019 7:30 AM - PR NewsWire Algernon Pharmaceuticals Announces Emoxypine (NP-178), a Top Selling Drug in Russia, as its Lead Drug for Inflammatory Bowel Disease August 2, 2019 7:00 AM - Globe NewsWire Algernon Pharmaceuticals Announces Russian Athletic Performance Enhancing Drugs Bemethyl (NP-135) and Bromantane (NP-160) Exhibited Potent Anti-Fibrotic Activity in NASH and CKD Studies July 31, 2019 7:00 AM - Globe NewsWire Cancer drug Keytruda, vaccines propel Merck to quarterly profit beat July 30, 2019 7:13 AM - StreetInsider Ashley Tisdale Joins The Allergan 'Women Who Know' Campaign July 29, 2019 7:30 AM - PR NewsWire Pfizer to spinoff, merge off-patent drugs unit with Mylan July 29, 2019 7:01 AM - StreetInsider Algernon Pharmaceuticals Announces Ifenprodil (NP-120) an NDMA Receptor Antagonist as its Lead Drug That Reduced Fibrosis in a Recent Idiopathic Pulmonary Fibrosis Study by 56% July 29, 2019 7:01 AM - Globe NewsWire Allergan (AGN), Editas Medicine (EDIT) Commence Brilliance Phase 1/2 Clinical Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10 July 25, 2019 9:03 AM - StreetInsider Allergan and Editas Medicine Initiate the Brilliance Phase 1/2 Clinical Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10 July 25, 2019 9:01 AM - StreetInsider Allergan and Editas Medicine Initiate the Brilliance Phase 1/2 Clinical Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10 July 25, 2019 9:00 AM - Globe NewsWire Allergan (AGN) Voluntarily Recalls BIOCELL Textured Breast Implants and Tissue Expanders July 24, 2019 8:34 AM - StreetInsider Allergan Voluntarily Recalls BIOCELL® Textured Breast Implants and Tissue Expanders July 24, 2019 8:30 AM - PR NewsWire Allergan (AGN) option implied volatility low into quarterly results and outlook July 23, 2019 10:45 AM - StreetInsider Allergan (AGN) Declares $0.74 Quarterly Dividend; 1.8% Yield July 19, 2019 7:34 AM - StreetInsider Allergan Declares Third Quarter 2019 Cash Dividend of $0.74 Per Ordinary Share July 19, 2019 7:30 AM - PR NewsWire Amgen (AMGN), Allergan (AGN) Report FDA Approval for MVASI (bevacizumab-awwb) and KANJINTI (trastuzumab-anns); Announce U.S. Availability July 19, 2019 6:44 AM - StreetInsider Amgen And Allergan's MVASI™ (bevacizumab-awwb) And KANJINTI™ (trastuzumab-anns) Now Available In The United States July 18, 2019 11:00 PM - PR NewsWire SVB Leerink Downgrades Allergen (AGN) to Market Perform July 18, 2019 5:11 AM - StreetInsider Allergan (AGN) Announces U.S. FDA Accepts NDA for Bimatoprost Sustained-Release in Patients with Open-Angle Glaucoma or Ocular Hypertension July 17, 2019 7:31 AM - StreetInsider U.S. FDA Accepts Allergan's New Drug Application for Bimatoprost Sustained-Release in Patients with Open-Angle Glaucoma or Ocular Hypertension July 17, 2019 7:30 AM - PR NewsWire Bernstein Downgrades Allergen (AGN) to Market Perform July 16, 2019 6:17 AM - StreetInsider Form DEFA14A Allergan plc July 12, 2019 5:16 PM - SEC Filing Allergan (AGN) Announces 29 Presentations at American Headache Society Meeting July 9, 2019 7:43 AM - StreetInsider Allergan Continues to Demonstrate Leadership in Migraine with 29 Presentations at the 2019 American Headache Society Annual Meeting July 9, 2019 7:42 AM - PR NewsWire Form DEFA14A Allergan plc July 8, 2019 4:47 PM - SEC Filing Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Boards of Directors of Oritani, Allergan, NRC, and Shore Community Bank on Behalf of Stockholders and Encourages Investors to July 3, 2019 2:49 PM - StreetInsider Allergen (AGN) PT Raised to $185 at SunTrust July 3, 2019 7:46 AM - StreetInsider Algernon Pharmaceuticals’ NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56% Outperforming USFDA Approved Treatments Nintedanib and Pirfenidone July 3, 2019 7:01 AM - Globe NewsWire Form DEFA14A Allergan plc July 2, 2019 6:14 AM - SEC Filing Stocks with Implied Volatility Movement July 2, 2019 4:47 AM - StreetInsider Form DEFA14A Allergan plc June 28, 2019 5:24 PM - SEC Filing Form DEFA14A Allergan plc June 28, 2019 5:22 PM - SEC Filing Form DEFA14A Allergan plc June 28, 2019 5:17 PM - SEC Filing Form DEFA14A Allergan plc June 28, 2019 5:15 PM - SEC Filing U.S. dominates second quarter global M&A as mega deals roll on June 28, 2019 1:24 AM - StreetInsider Form DEFA14A Allergan plc June 27, 2019 4:39 PM - SEC Filing Form DEFA14A Allergan plc June 27, 2019 6:31 AM - SEC Filing Stocks with Implied Volatility Movement June 27, 2019 4:49 AM - StreetInsider Form DEFA14A Allergan plc June 26, 2019 4:50 PM - SEC Filing Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Allergan plc (NYSE: AGN) on Behalf of Allergan Shareholders and Encourages Allergan Investors to Contact the Firm June 26, 2019 4:33 PM - StreetInsider Elliott Holds 2.5% Interest in Allergan (AGN), Supports AbbVie (ABBV) Takeover - Bloomberg June 26, 2019 10:28 AM - StreetInsider Allergen (AGN) PT Raised to $178 at RBC Capital June 26, 2019 6:42 AM - StreetInsider Increasing unusual put option volume: EXTR TV PE AGN EDIT ABBV DAN AMC June 26, 2019 4:43 AM - StreetInsider Stocks with Implied Volatility Movement June 26, 2019 4:33 AM - StreetInsider Mizuho Securities Downgrades Allergen (AGN) to Neutral Following AbbVie Acquisition June 26, 2019 4:31 AM - StreetInsider Form 8-K Allergan plc For: Jun 25 June 25, 2019 5:20 PM - SEC Filing Form DEFA14A Allergan plc June 25, 2019 5:18 PM - SEC Filing Allergan (AGN)/AbbVie (ABBV) Deal Spread Closes at Wide 9.1% on First Day June 25, 2019 4:36 PM - StreetInsider Abbvie (ABBV) Deal for Allergan (AGN) Offers 'Limited Strategic Sense' - BofA/Merrill Lynch June 25, 2019 12:59 PM - StreetInsider Barclays Upgrades Allergen (AGN) to Equalweight, Following Takeover Bid June 25, 2019 12:52 PM - StreetInsider Increasing unusual option volume: EXTR RPM CCK SBGL RMD AGN ABBV June 25, 2019 11:14 AM - StreetInsider Allergan (AGN) June weekly put volume and option implied volatility increases June 25, 2019 10:22 AM - StreetInsider Pre-Open Movers 06/25: (AGN) (PHUN) (PYX) (GRUB) (ALDX) (ABBV) (BHF) (AKRX) (more) June 25, 2019 8:55 AM - StreetInsider AGN/ABBV Deal Good for Pharma Space - Cantor Fitzgerald June 25, 2019 8:44 AM - StreetInsider Ironwood Pharma (IRWD) Highlighted Amid Partnership with AGN Post Deal June 25, 2019 8:07 AM - StreetInsider Allergan (AGN) calls active into report of AbbVie (ABBV) deal June 25, 2019 6:46 AM - StreetInsider AbbVie (ABBV) Announces Agreement to Acquire Allergan (AGN) in $63 Billion Deal June 25, 2019 6:44 AM - StreetInsider AbbVie to Acquire Allergan in Transformative Move for Both Companies June 25, 2019 6:43 AM - PR NewsWire Teva Pharma (TEVA), Mylan (MYL) on Watch on ABBV/AGN Headlines June 25, 2019 6:35 AM - StreetInsider AbbVie (ABBV) Nears Deal to Buy Allergan (AGN) for More Than $60 Billion - WSJ June 25, 2019 6:27 AM - StreetInsider Allergen (AGN) PT Lowered to $171 at Mizuho Securities On Lower Botox and CoolSculpt Revs June 25, 2019 6:02 AM - StreetInsider Allergan (AGN) Receives FDA Clearance For CoolTone Device June 24, 2019 7:30 AM - StreetInsider Allergan Receives FDA Clearance For CoolTone™ Device June 24, 2019 7:30 AM - PR NewsWire Full Article List